anti-DPP4 (DPP4) Antikörper

Human Dipeptidyl-Peptidase 4 (DPP4) Interaktionspartner

1. DPP4 is an AR-stimulated tumor suppressor gene that is downregulated during progression to castration-resistant prostate cancer; treatment with DPP4 inhibitors, commonly used to treat type 2 diabetes, may accelerate prostate cancer progression following androgen deprivation therapy

2. The authors provide evidence that DPP4, the Middle East respiratory syndrome coronavirus receptor, is upregulated in the lungs of smokers and chronic obstructive pulmonary disease patients, which could partially explain why these individuals are more susceptible to Middle East respiratory syndrome coronavirus infection.

3. In the light of the downmodulating role of CD26 in major chemokines.

4. DPP4 levels were found to be increased in polycystic ovary syndrome patients compared to controls.

5. Data indicate that lncRNA-OIS1 links oncogenic induction and senescence with the activation of the tumor suppressor DPP4.

6. Constitutive DPP4 activity is positively associated with lean mass, central adiposity, and insulin resistance and negatively to general adiposity.

7. CD26 mRNA expression in rheumatoid arthritis patients is associated with disease activity and bone erosion

8. While in anti-neutrophil cytoplasmic auto-antibody (ANCA)-associated vasculitis (AAV) patients (n = 29) CD26 was increased on CD4(+) lymphocytes, CD39 and CD73 were generally reduced on patients' T-cells.

9. Serum DPP-IV may be a predictive biomarker for PTC diagnosis and prognosis in Chinese male patients.

10. Low DPP4 expression is associated with microalbuminuria in patients with type 1 diabetes.

11. dipeptidyl peptidase IV (DPP IV) might play role(s) in amyloid formation and is upregulated in Alzheimer's brain neurons and occurs in multiple amyloid plaques.

12. CRABP1, COL11A1, FMO2, PRG4, or C2ORF40. Immunofluorescent staining confirmed that SFRP2 and FMO1 define cell types of dramatically different morphology.

13. DPP-4, besides playing a role in incretin effects, directly affects beta cell function and survival.

14. Plasma levels of DPP4 were decreased in patients with rheumatoid arthritis or systemic sclerosis, compared to controls.

15. Fluctuation in the levels of DPP4 does not play an important role in prognosis, early detection and diagnosis of medullary thyroid cancer.

16. there is a CD26-related linkage with USP22 in Malignant pleural mesothelioma cell inhibition induced by anti-CD26 monoclonal antibody HuCD26mAb

17. Results show a high serum DPP4 activity in hepatocellular carcinoma (HCC) and associated with poor clinical prognosis. Genetic ablation of DPP4 or treatment with its inhibitor (vildagliptin) prevented high-fat diet (HFD)-induced HCC. Also, HFD-induced DPP4 activity facilitated HCC angiogenesis and cancer cell metastasis. These results revealed a link between obesity-related high serum DPP4 activity and HCC progression.

18. Constitutive DPP4 activity was associated with early markers of endothelial proinflammatory activation and microvascular function, and may have an influence and even be influenced by inflammation and microvascular blood flow in subjects with excess body weight without diabetes.

19. Data on CD26/dipeptidyl peptidase IV (CD26)-mediated immune regulation suggest that CD26 may be an appropriate therapeutic target for the treatment of selected immune disorders [Review].

20. Study provides mechanistic insights into the molecular interaction between KLK5 and DPP4 as well as CD4+ T cell derived KLK5 mediated enzymatic cleavage of DPP4 from cell surface. Study uncovers a hitherto unknown cellular source and mechanism behind enhanced plasma DPP4 activity in T2DM.

Cow (Bovine) Dipeptidyl-Peptidase 4 (DPP4) Interaktionspartner

1. Results describe a proline-rich cytokine from neurosecretory granules that represents a new natural substrate for Dipeptidyl Peptidase IV (DPPIV).

2. This and other dipeptidyl peptidases can be isolated from bovine testes.

3. Data demonstrate that dipeptidyl peptidase II can form a complex with adenosine deaminase, but with one order of magnitude higher dissociation constant than that of DPPIV.

Pig (Porcine) Dipeptidyl-Peptidase 4 (DPP4) Interaktionspartner

1. This study shows that porcine DPP-IV is generally inhibited with greater potency by protein-derived peptides than is the human enzyme

2. DPP-IV from porcine kidney cortex was characterized.

3. Neutral endopeptidase 24.11 and DPP-IV is superior to DPP-IV inhibition alone in preserving intact GLP-1, which implies possibility that the combination has therapeutic potential.

4. Results describe the distribution of dipeptidyl peptidase IV-like activity enzymes in porcine tissue sections by RT-PCR.

Xenopus laevis Dipeptidyl-Peptidase 4 (DPP4) Interaktionspartner

1. Dpp4 and Xnr1 showed synergistic effect on induction of ectopic dorsal body axis, when co-injected at suboptimal doses in early embryos. Overexpression of Dpp4 disrupted specification of dorsal body axis of embryo, leading to malformed phenotypes such as spina bifida and a shortened and dorsally bent axis.

Mouse (Murine) Dipeptidyl-Peptidase 4 (DPP4) Interaktionspartner

1. The effects of sitagliptin, a DPP4 inhibitor in wide clinical use, on LPS-induced lung injury in mice.

2. The effect of CD26-deficiency on dipeptidyl peptidase 8 and 9 expression profiles in a mouse model of Crohn's disease.

3. Findings indicate interleukin 33 (IL-33)- and eosinophil-mediated tumor control, revealed when endogenous mechanisms of dipeptidylpeptidase 4 (DPP4) immunoregulation are inhibited.

4. Of the six biomarkers, only COMP and DPP4 showed high and SPP1 moderate correlation with the spinal muscular atrophy phenotype. PLS3 overexpression neither influenced the SMN level nor the six biomarkers, supporting the hypothesis that PLS3 acts as an independent protective modifier.

5. These data indicate that DPP-4 is modulated in a tissue specific manner and is dependent on physiological conditions such as hyperglycaemia and insulin resistance, suggesting a significant role in disorders such as diabetes.

6. DPP4 activity when compared to healthy controls. Analysis of Dpp4-Liv-Tg mice revealed elevated systemic DPP4 activity and diminished active GLP-1 levels.

7. hepatocyte DPP4 promotes visceral adipose tissue inflammation and insulin resistance in obesity, and targeting this pathway may have metabolic benefits that are distinct from those observed with oral DPP4 inhibitors

8. DPP-4 inhibition with linagliptin slowed the progression of premature aging in klotho-/- mice. Provide a novel insight into the potential role of DPP-4 in the mechanism of premature aging.

9. Chronic stress accelerates DPP4-mediated GLP-1 degradation and alters plasma adiponectin, accelerating vascular senescence and impairing ischemia-induced neovascularization.

10. p53 limits ferroptosis of colorectal cancer cells by blocking DPP4 activity.

11. DPP4 can regulate chronic stress-induced hematopoietic stemc cell activation and inflammatory cell production via an Adrbeta3/CXCL12-dependent mechanism that is mediated by the GLP-1/GLP-1R axis.

12. DPPIV-knockout mice showed attenuation of scratching in psoriatic pruritus disease model.

13. Actions of several substrate chemokines might be potentiated by downregulation of DPP-4, synergistically with upregulation of chemokines and their receptors in adipose tissues of obese mice.

14. Inhibition of DPP-4 activity by linagliptin reverses Western diet-induced diastolic dysfunction, possibly by targeting TRAF3IP2 expression and its downstream inflammatory signaling.

15. DPP4 is pro-fibrotic in Carbon tetrachloride-induced liver fibrosis.

16. systemic DPP4 inhibition restores the impaired mononuclear cell homing in Eng+/- animals post-myocardial infarction, and enhances cardiac repair, which might be explained by restoring the balance between the inflammatory and regenerative macrophages present in the heart

17. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Effects are augmentated of the by DPP4 inhibitor Saxagliptin.

18. DPP-4 inhibitor teneligliptin inhibited atherogenesis in ApoE knockout mice, at least partially, through attenuation of the inflammatory phenotype of perivascular adipose tissue.

19. Increased plasma DPP-4 activity may correlate with aneurysmal development. CD26 on monocytes plays a critical role in cell differentiation, possibly mediated by extracellular signal-regulated protein kinase 1/2-p21 axis signaling pathways and cytoskeletal proteins reassembly.

20. High DPP4 expression is associated with cardiac ischemia and systolic dysfunction.